381 related articles for article (PubMed ID: 19609076)
21. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy.
Cohen MP; Clements RS; Hud E; Cohen JA; Ziyadeh FN
Exp Nephrol; 1996; 4(3):166-71. PubMed ID: 8773479
[TBL] [Abstract][Full Text] [Related]
22. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease.
Peng CY; Sankaran D; Ogborn MR; Aukema HM
Exp Biol Med (Maywood); 2009 Jul; 234(7):737-43. PubMed ID: 19429858
[TBL] [Abstract][Full Text] [Related]
23. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Knight S; Johns EJ
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice.
Sakaguchi M; Isono M; Isshiki K; Sugimoto T; Koya D; Kashiwagi A
Biochem Biophys Res Commun; 2006 Feb; 340(1):296-301. PubMed ID: 16364254
[TBL] [Abstract][Full Text] [Related]
25. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes.
DiPetrillo K; Coutermarsh B; Gesek FA
Am J Physiol Renal Physiol; 2003 Jan; 284(1):F113-21. PubMed ID: 12388406
[TBL] [Abstract][Full Text] [Related]
26. Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.
Réti A; Pap E; Zalatnai A; Jeney A; Kralovánszky J; Budai B
Anticancer Res; 2009 Aug; 29(8):3095-101. PubMed ID: 19661321
[TBL] [Abstract][Full Text] [Related]
27. Prevention and treatment of diabetic nephropathy.
Wittmann I; Molnár GA; Degrell P; Wagner Z; Tamaskó M; Laczy B; Brasnyó P; Wagner L; Nagy J
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S36-42. PubMed ID: 15955373
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice.
Elmarakby AA; Ibrahim AS; Faulkner J; Mozaffari MS; Liou GI; Abdelsayed R
Vascul Pharmacol; 2011; 55(5-6):149-56. PubMed ID: 21807121
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.
Nakhoul FM; Miller-Lotan R; Awad H; Asleh R; Jad K; Nakhoul N; Asaf R; Abu-Saleh N; Levy AP
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F830-8. PubMed ID: 19176700
[TBL] [Abstract][Full Text] [Related]
30. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Williams ME; Bolton WK; Khalifah RG; Degenhardt TP; Schotzinger RJ; McGill JB
Am J Nephrol; 2007; 27(6):605-14. PubMed ID: 17823506
[TBL] [Abstract][Full Text] [Related]
31. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.
Lu A; Miao M; Schoeb TR; Agarwal A; Murphy-Ullrich JE
Am J Pathol; 2011 Jun; 178(6):2573-86. PubMed ID: 21641382
[TBL] [Abstract][Full Text] [Related]
32. Arginase-2 mediates diabetic renal injury.
Morris SM; Gao T; Cooper TK; Kepka-Lenhart D; Awad AS
Diabetes; 2011 Nov; 60(11):3015-22. PubMed ID: 21926276
[TBL] [Abstract][Full Text] [Related]
33. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats.
Komers R; Lindsley JN; Oyama TT; Anderson S
Clin Exp Pharmacol Physiol; 2007; 34(1-2):36-41. PubMed ID: 17201733
[TBL] [Abstract][Full Text] [Related]
34. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice.
Fujita H; Fujishima H; Takahashi K; Sato T; Shimizu T; Morii T; Shimizu T; Shirasawa T; Qi Z; Breyer MD; Harris RC; Yamada Y; Takahashi T
Metabolism; 2012 Dec; 61(12):1714-24. PubMed ID: 22632894
[TBL] [Abstract][Full Text] [Related]
35. Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner.
Kim SR; Park JH; Lee ME; Park JS; Park SC; Han JA
Mech Ageing Dev; 2008 Dec; 129(12):706-13. PubMed ID: 18848576
[TBL] [Abstract][Full Text] [Related]
36. Dietary soy protein reduces early renal disease progression and alters prostanoid production in obese fa/fa Zucker rats.
Hwang SY; Taylor CG; Zahradka P; Bankovic-Calic N; Ogborn MR; Aukema HM
J Nutr Biochem; 2008 Apr; 19(4):255-62. PubMed ID: 17656081
[TBL] [Abstract][Full Text] [Related]
37. New and old markers of progression of diabetic nephropathy.
Jerums G; Premaratne E; Panagiotopoulos S; Clarke S; Power DA; MacIsaac RJ
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S30-7. PubMed ID: 18937992
[TBL] [Abstract][Full Text] [Related]
38. Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops.
Hall AJ; Babish JG; Darland GK; Carroll BJ; Konda VR; Lerman RH; Bland JS; Tripp ML
Phytochemistry; 2008 May; 69(7):1534-47. PubMed ID: 18358504
[TBL] [Abstract][Full Text] [Related]
39. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice.
Ezquer F; Ezquer M; Simon V; Pardo F; Yañez A; Carpio D; Conget P
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1354-65. PubMed ID: 19822294
[TBL] [Abstract][Full Text] [Related]
40. Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice.
Hathaway CK; Gasim AM; Grant R; Chang AS; Kim HS; Madden VJ; Bagnell CR; Jennette JC; Smithies O; Kakoki M
Proc Natl Acad Sci U S A; 2015 May; 112(18):5815-20. PubMed ID: 25902541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
